Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial

VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to announce the topline results from the ACcomplisH China Phase 2 Trial in children with achondroplasia (ACH) aged 2 to 10 years. In the trial, patients dosed…